Arcturus Therapeutics Holdings Inc.
$265.34M- Market cap
- $444.25M
- Debt
- +$52.00M
- Cash
- −$230.91M
Capital structure 90% equity / 10% debt · EV / Revenue 3.23x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ARCT stock price vs MELI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MELI's multiple
Needs MELI P/S.
Implied fair value · at ARCT's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ARCT FY 2025 (ended Dec 31, 2025) · MELI FY 2025 (ended Dec 31, 2025).
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 90% equity / 10% debt · EV / Revenue 3.23x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ARCTURUS THERAPEUTICS HOLDINGS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
MercadoLibre, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.24x
1.36x
Net debt / EBITDA
Leverage against operating earnings
2.72x
0.84x
Cash and equivalents
Liquid reserves on the balance sheet
$230.91M
$6.30B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ARCT vs MRNA
BioNTech SE
ARCT vs BNTX
ALNYLAM PHARMACEUTICALS, INC.
ARCT vs ALNY
Sarepta Therapeutics, Inc.
ARCT vs SRPT
Intellia Therapeutics, Inc.
ARCT vs NTLA
AMAZON COM INC
ARCT vs AMZN
DoorDash, Inc.
ARCT vs DASH
Sea Ltd
ARCT vs SE
EBAY INC
ARCT vs EBAY
PDD Holdings Inc.
ARCT vs PDD
JD.com, Inc.
ARCT vs JD
$52.00M
$9.19B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.